

Resource Summary Report

Generated by [nidm-terms](#) on Sep 21, 2026

Reata Pharmaceuticals

RRID:SCR_004040

Type: Tool

Proper Citation

Reata Pharmaceuticals (RRID:SCR_004040)

Resource Information

URL: <http://www.reatapharma.com/>

Proper Citation: Reata Pharmaceuticals (RRID:SCR_004040)

Description: Pharmaceutical company focused on investigating experimental oral antioxidative and anti-inflammatory drugs, which dually activate the antioxidative transcription factor Nrf2 (Nuclear factor (erythroid-derived 2)-like 2) and inhibit the pro-inflammatory transcription factor NF-B (nuclear factor kappa-light-chain-enhancer of activated B cells). The antioxidative and anti-inflammatory compounds bardoxolone methyl and RTA 408 are the lead clinical development compounds in their portfolio.

Abbreviations: Reata

Synonyms: Reata Pharmaceuticals Inc.

Resource Type: commercial organization

Keywords: pharmaceutical, drug, immuno-oncology, ophthalmology, cardiovascular, autoimmune, respiratory, antioxidant inflammation modulator, oxidative stress, medicine, dermatology, skin, eye, clinical trial, nrf2, nf-b, bardoxolone methyl, rta 408, transcription, dna, transcription factor

Resource Name: Reata Pharmaceuticals

Resource ID: SCR_004040

Alternate IDs: nlx_158468

Record Creation Time: 20220129T080222+0000

Record Last Update: 20260919T195031+0000

Ratings and Alerts

No rating or validation information has been found for Reata Pharmaceuticals.

No alerts have been found for Reata Pharmaceuticals.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 2 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Chambel SS, et al. (2015) The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism. BioMed research international, 2015, 597134.

, et al. (2005) Corporate Activity - Mergers and Acquisitions. Pharmaceutical & diagnostic innovation, 3(6), 19.